Multiple Myeloma | Specialty

Dr. Marron on an Adjuvant Personalized Neoantigen Peptide Vaccine for Several Malignancies

April 10th 2021

Thomas Urban Marron, MD, PhD, discusses primary objectives of a study examining the use of an adjuvant personalized neoantigen peptide vaccine in several malignancies.

Daratumumab Consolidation Appears Safe, Shows Encouraging Efficacy in Very Good Responders With Myeloma

April 9th 2021

Daratumumab appears to be safe when used as consolidation therapy in patients with multiple myeloma, even soon after autologous stem cell transplant, and the agent has also demonstrated early efficacy in the setting of very good responders.

Dr. Shah on Managing CAR T-Cell Therapy–Related Toxicities in Multiple Myeloma

April 7th 2021

Nina Shah, MD, discusses the management of CAR T-cell therapy–related toxicities in multiple myeloma.

Selinexor, Bortezomib, and Dexamethasone Combination Proves Effective for Myeloma

April 7th 2021

In December 2020, the FDA approved selinexor in combination with the proteasome inhibitor bortezomib and dexamethasone for patients with MM who have received at least 1 prior therapy.

Rolling Submission to FDA Completed for Cilta-Cel for Relapsed/Refractory Multiple Myeloma

April 6th 2021

The rolling submission of a biologics license application to support the approval of the investigational BCMA-directed CAR T-cell therapy ciltacabtagene autoleucel for the treatment of patients with relapsed/refractory multiple myeloma has been completed.

Dr. Martin on the Safety Profile of Bispecific T-Cell Engagers in Multiple Myeloma

April 5th 2021

Thomas G. Martin, MD, discusses the safety profile of bispecific T-cell engagers in multiple myeloma.

Dr. Kumar on the Evolving Role of Venetoclax in Relapsed/Refractory Multiple Myeloma

April 1st 2021

Shaji K. Kumar, MD, discusses the evolving role of venetoclax in relapsed/refractory multiple myeloma.

FDA Approves Isatuximab Plus Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma

March 31st 2021

The FDA has approved isatuximab in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously received 1 to 3 lines of therapy.

NCCN Guidelines Include an Abundance of Options Across Multiple Myeloma Paradigm

March 30th 2021

The National Comprehensive Cancer Network guidelines for the management of frontline and relapsed/refractory multiple myeloma were updated to incorporate novel agents and combination strategies, providing a wide range of category 1 recommended therapies for patients.

Selinexor/Dexamethasone Approved in Europe for Relapsed/Refractory Multiple Myeloma

March 29th 2021

The European Commission has granted conditional marketing authorization for selinexor for use in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have previously received at least 4 therapies and whose disease is refractory to at least 2 proteasome inhibitors, 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody, and have experienced progressive disease on their last therapy.

x